High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions

被引:70
作者
Li, Guannan [1 ]
Huang, Ke [1 ]
Nikolic, Dejan [1 ]
van Breemen, Richard B. [1 ]
机构
[1] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, NIH,Ctr Bot Dietary Supplements Res, Chicago, IL 60612 USA
基金
美国国家卫生研究院;
关键词
IN-VITRO COCKTAIL; HUMAN LIVER-MICROSOMES; ENZYMES; METABOLISM; ISOFORMS; P450S; GOLDENSEAL; RUN;
D O I
10.1124/dmd.115.065987
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Detection of drug-drug interactions is essential during the early stages of drug discovery and development, and the understanding of drug-botanical interactions is important for the safe use of botanical dietary supplements. Among the different forms of drug interactions that are known, inhibition of cytochrome P450 (P450) enzymes is the most common cause of drug-drug or drug-botanical interactions. Therefore, a rapid and comprehensive mass spectrometry-based in vitro high-throughput P450 cocktail inhibition assay was developed that uses 10 substrates simultaneously against nine CYP isoforms. Including probe substrates for CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and two probes targeting different binding sites of CYP3A4/5, this cocktail simultaneously assesses at least as many P450 enzymes as previous assays while remaining among the fastest due to short incubation times and rapid analysis using ultrahigh pressure liquid chromatography-tandem mass spectrometry. The method was validated using known inhibitors of each P450 enzyme and then shown to be useful not only for single-compound testing but also for the evaluation of potential drug-botanical interactions using the botanical dietary supplement licorice (Glycyrrhiza glabra) as an example.
引用
收藏
页码:1670 / 1678
页数:9
相关论文
共 42 条
[1]
A rapid ultra-performance liquid chromatography/tandem mass spectrometric methodology for the in vitro analysis of Pooled and Cocktail cytochrome P450 assays [J].
Alden, Peter G. ;
Plumb, Robert S. ;
Jones, Michael D. ;
Rainville, Paul D. ;
Shave, Darcy .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2010, 24 (01) :147-154
[2]
Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine [J].
Bertelsen, KM ;
Venkatakrishnan, K ;
Von Moltke, LL ;
Obach, RS ;
Greenblatt, DJ .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :289-293
[3]
Busby WF, 1999, DRUG METAB DISPOS, V27, P246
[4]
Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components [J].
Chatterjee, P ;
Franklin, MR .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (11) :1391-1397
[5]
Chauret N, 1998, DRUG METAB DISPOS, V26, P1
[6]
Davis A., 2014, The handbook of medicinal chemistry: principles and practice
[7]
Dey A., 2013, Cytochrome P450 2E1: Its Role in Disease and Drug Metabolism, V1st
[8]
Dierks EA, 2001, DRUG METAB DISPOS, V29, P23
[9]
Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse [J].
Dinger, Julia ;
Meyer, Markus R. ;
Maurer, Hans H. .
TOXICOLOGY LETTERS, 2014, 230 (01) :28-35
[10]
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes [J].
Eagling, VA ;
Tjia, JF ;
Back, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (02) :107-114